雌、孕激素受体在非小细胞肺癌组织中的表达及临床意义的研究

Expression of Estrogen and Progesterone Receptors in Nonsmallcell Lung Cancer and its Clinical Significance

目的：探讨雌激素受体（ＥＲ）、孕激素受体（ＰＲ）在非小细胞肺癌组织中的分布规律，对预后的影响和肺癌内分泌治疗的可能性。方法：采用免疫组化方法对１２２例肺癌组织中的ＥＲ、ＰＲ进行检测。结果：正常肺组织中ＥＲ、ＰＲ均不表达。癌组织中ＥＲ、ＰＲ阳性率分别为４６．７％和５０％。ＥＲ、ＰＲ在各年龄组、性别、组织学类型、临床分期及淋巴结有否转移之间无显著差异（Ｐ＞０．０５），而与癌组织分化程度及预后关系密切。癌组织分化程度愈高，ＥＲ及ＰＲ阳性率愈高（Ｐ＜０．０５）。ＥＲ阳性的５年生存率为４１．２％，高于ＥＲ阴性者（１６．７％）（Ｐ＜０．０５）），ＰＲ阳性的５年生存率为４４％，显著高于ＰＲ阴性者（１４．０％）（Ｐ＜０．０１）。结论：ＥＲ、ＰＲ可以作为判定肺癌预后和恶性程度的指标；雌激素可能通过ＥＲ、ＰＲ对部分肺癌的发生发展起作用，对其采用内分泌治疗有可能取得效果。

Objective: We investigated the relation of Estrogen receptors (ER) and progesterone receptors (PR) in the lung cancer with prognosis and tested the feasibility of clinical endocrinotherapy. Methods:ER and PR in 122 nonsmallcell lung cancer tissue specimens were assayed by immunohistochemical method. Results:ER and PR were negative in all normal lung tissue, the positive rate of ER and PR in lung cancer was 46. 7% and 50% respectively. We found no correlation between ER(PR) content and age, sex, histologic subtype, clinical classification or metastasis of regional lymphnodes, respectively. The 5year survival rate for ER positive patients (41.2%) was higher than that for ER negative patients (16.7%)(P<005), and the 5year survival rate for PR positive patients (44%) was higher than that for PR negative patients (14.0%)(P<001). The positive rates of ER and PR in welldifferentiated cancer tissue were higher than that in poorlydifferentiated cancer tissue(P<005). Conclusions: We concluded that ER and PR could be used as biological markers to judge prognosis and the malignant degree of nonsmallcell lung cancer. Selected cases of lung cancer might respond favorably to endocrinal therapy.